Subject: Enzo Stock Booms on DNA Probe News
Date: Published: 12/5/91 (28 lines)
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

    Abreast of the Market:
    Industrials Lose 17.89 as Reports
    On Economy Still Show Softness
    ----
    By Craig S. Smith
    Staff Reporter of The Wall Street Journal

[82 lines irrelevant to AIDS removed.  --sysop]

    Enzo Biochem rocketed 4 1/2 to 5 5/8.  The company unveiled
 a non-radioactive DNA probe to detect HIV, which causes AIDS.  
 The probe is currently available for research only.  Enzo's
 gains were good news for holders of Engex Inc., a closed-end
 investment fund, which owns about 300,000 Enzo shares.
    Enzo is one of Engex's largest holdings.  Based on the
 latest figures available, the gains add about $1.43 a share
 to Engex's net asset value, according to Thomas J. Herzfeld,
 a closed-end fund investment adviser.  Engex rose 3/4 to 8
 1/4, but is still trading at about a 24% discount to its net
 asset value.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]